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ABSTRACT: Amylin is coexpressed with insulin in pancreatic islet β-
cells and has potent effects on gastric emptying and food intake. The
effect of amylin on satiation has been postulated to involve AMY3
receptors (AMY3R) that are heteromers of the calcitonin receptor
(CTR) and receptor activity-modifying protein 3 (RAMP3). Under-
standing the molecular control of signaling through the AMY3R is thus
important for peptide drug targeting of this receptor. We have
previously used alanine scanning mutagenesis to study the contribution
of the extracellular surface of the CTR to binding and signaling
initiated by calcitonin (CT) and related peptides (Dal Maso, E., et al.
(2019) The molecular control of calcitonin receptor signaling. ACS
Pharmacol. Transl. Sci. 2, 31−51). That work revealed ligand- and
pathway-specific effects of mutation, with extracellular loops (ECLs) 2
and 3 particularly important in the distinct propagation of signaling
mediated by individual peptides. In the current study, we have used equivalent alanine scanning of ECL2 and ECL3 of the CTR
in the context of coexpression with RAMP3 to form AMY3Rs, to examine functional affinity and efficacy of peptides in cAMP
accumulation and extracellular signal-regulated kinase (ERK) phosphorylation (pERK). The effect of mutation was determined
on representatives of the three major distinct classes of CT peptide, salmon CT (sCT), human CT (hCT), and porcine CT
(pCT), as well as rat amylin (rAmy) or human α-CGRP (calcitonin gene-related peptide, hCGRP) whose potency is enhanced
by RAMP interaction. We demonstrate that the dynamic nature of CTR ECL2 and ECL3 in propagation of signaling is
fundamentally altered when complexed with RAMP3 to form the AMY3R, despite only having predicted direct interactions with
ECL2. Moreover, the work shows that the role of these loops in receptor signaling is highly peptide dependent, illustrating that
even subtle changes to peptide sequence may change signaling output downstream of the receptor.
KEYWORDS: amylin receptor, calcitonin receptor, receptor activity-modifying protein, G protein-coupled receptor,
receptor structure−function, cell signaling
■ INTRODUCTION
G protein-coupled receptors (GPCRs) are the largest super-
family of cell surface protein conduits of extracellular chemical
information to the inside of cells.1 As such, understanding the
molecular basis of how these extracellular signals are
conformationally propagated through the GPCR to recruit
and activate signal transducers is critically important to
development of novel therapeutics that regulate this process.
Moreover, GPCRs can recruit multiple different transducers
and other regulatory proteins and this can be altered in a
ligand-specific manner, leading to biased agonists that hold
promise as precision medicines to treat various diseases.2
Class B1 GPCRs are an important subfamily for key
physiological peptides that regulate diverse functions including
energy homeostasis, bone metabolism, immune function,
lymph and vascular formation, and the control of vascular
tone.3 The calcitonin receptor (CTR) is a broadly expressed
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class B1 GPCR that is most recognized for its expression in
bone resorbing osteoclasts, and its role in bone metabolism.4
However, CTRs also interact with a family of 3 receptor
activity-modifying proteins (RAMPs) to yield high affinity
receptors for amylin and calcitonin gene-related peptide
(CGRP).5 These are termed AMY1, AMY2, and AMY3
receptors according to the interacting RAMP, i.e., RAMP1,
RAMP2, and RAMP3, respectively. In addition to modifying
the binding specificity of the CT family of receptors, a major
consequence of GPCR-RAMP interaction is alteration to the
signaling profile of the receptor,6 and this has been observed
for the AMY receptors relative to CTR alone.7
Amylin is coexpressed with insulin in pancreatic islet β-cells
and has potent effects on gastric emptying and food intake.8
Pramlintide, a nonamyloidogenic analogue of human amylin is
approved for the treatment of type 1 diabetes in combination
with insulin.8 However, amylin analogues also promote
satiation and can lead to significant weight loss in overweight
patients, and cause marked weight loss in animal models of
obesity when coadministered with other agents that promote
weight loss, such as glucagon-like peptide-1 (GLP-1) receptor
agonists or leptin.9,10 Accordingly, there is significant interest
in the development of new amylin analogues to better treat
obesity.8
The amylin effect on satiation has been localized to amylin
receptors in the area postrema and has been proposed to
involve the AMY3R subtype (CTR:RAMP3 heteromer),
11
although all three RAMPs are present in the area postrema.8
Understanding the molecular control of signaling through the
AMY3R is thus crucial for peptide drug targeting of this
receptor.
Recent advances in cryo-electron microscopy have allowed
determination of the structures of active state class B GPCRs
in complex with peptide agonists and the canonical Gs
protein,12−15 including complexes of the CTR12,16 and the
CGRP receptor.15 The latter is a hetromer of the related
calcitonin receptor-like receptor (CLR) and RAMP1. These
structures have allowed identification of the peptide binding
domain within the receptor core and serve as a template for 3-
dimensional (3D) mapping of the effect of mutation on
receptor function. Importantly, the solution of the CGRP
receptor (CGRPR) complex revealed a novel interface for
RAMP interaction with transmembrane helices 4 and 5 that
extended to parts of extracellular loop (ECL) 2,15 and allows
for the first-time structure-based modeling of related RAMP-
class B GPCR complexes.
We have previously used alanine scanning mutagenesis to
study the contribution of the extracellular surface of the CTR
to binding and signaling initiated by CT and related
peptides.16,17 This work revealed ligand- and pathway-specific
effects of mutation, with ECLs 2 and 3 particularly important
in the distinct propagation of signaling mediated by individual
peptides.17 In the current study, we have used equivalent
alanine scanning of ECL2 and ECL3 of the CTR in the context
of coexpression with RAMP3 to form AMY3Rs, in order to
examine functional affinity and efficacy of peptides in cAMP
accumulation and extracellular signal-regulated kinase (ERK)
phosphorylation (pERK). The effect of mutation was
determined on representatives of the three major distinct
classes of CT peptide, salmon CT (sCT), human CT (hCT),
and porcine CT (pCT), as well as rat amylin (rAmy) or human
α-CGRP (hCGRP) whose potency is enhanced by RAMP
interaction. The work illustrates that interaction with RAMP3
dynamically alters how ECL2 and ECL3 contribute to
propagation of signaling through the CTR.
■ RESULTS AND DISCUSSION
Importance of ECL2 and ECL3 in the Control of
AMY3R Function. To gain insight into the role of RAMP3 in
the AMY3R phenotype we performed alanine scanning
mutagenesis on CTR ECL2 (I279-I300) and ECL3 (F356-
M376) that play important roles in peptide binding and
propagation of signaling at the CTR in the absence of
RAMPs.17 Each of these mutants was analyzed for their effect
on cell surface expression (Figure 1), binding affinity in
Figure 1. Effect of alanine mutation on the cell surface expression of
the AMY3R and CTR. (A−C) AMY3R; (D−F) CTR (extracted from
Dal Maso et al, 201817). (A, D) Top view of the active, sCT-bound,
AMY3R (A) or CTR (6NIY) (D) model with the extracellular surface
subject to alanine scanning depicted in gray (A) or off-white (D)
(combined surface/cpk representation). The rest of the protein
complex is shown in ribbon representation. CTR (blue, AMY3R; dark
red, CTR), sCT peptide (dark red, AMY3R; aquamarine, CTR),
RAMP3 (green). The receptor ECD is omitted for clarity. (B, E) Map
of the effect of mutation on cell surface receptor expression colored
according to the legend in panel F. (C, F) Effect of alanine mutation
of ECL2 and ECL3 on CTR expression monitored by FACS of anti-c-
Myc antibody binding to the N-terminal c-Myc epitope on the
receptor. Data are normalized to the expression of the wild-type
(WT) receptor (100%). Significant differences in the level of cell
surface expression were determined by one-way ANOVA followed by
Dunnett’s post-test comparison to the WT. P < 0.05 was used to
denote significance, and colored according to the magnitude of
change. Individual values (separate experiments) are shown within the
bars.
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competitive radioligand binding assays (Figure 2, Table 1,
Figures S1−S6), and functional response (pERK and cAMP
accumulation) for each peptide (Figures 3−8, Figures S7−S16,
Tables 2−5). A homology model of the AMY3R complex was
built from deposited structures of the CTR (6NIY16) and
CGRPR (6E3Y;15 for initial positioning of RAMP3) active
complexes and subjected to a short molecular dynamics (MD)
simulation (200 ns) to resolve energetically unfavorable
interactions. This model was used to map effects of mutation
on the AMY3R and to enable comparison to the effects of
previously published equivalent mutations on the CTR,16,17
mapped onto the recently published 3.3 Å structure (6NIY)
that included ECL2 and ECL3 side chains16 (Figures 9−12).
Receptor Expression. AMY3Rs were expressed using a
Flp-In bicistronic vector of N-terminally tagged cMyc-CTR
and RAMP3, where the RAMP is overexpressed relative to the
CTR, and stable cell lines of each mutant receptor generated
by isogenic integration into Flp-In CV-1 cells. Anti-cMyc
antibody binding to the CTR was measured by FACS as a
marker of the cell surface expression of the AMY3R (Figure 1).
There was a marked decrease in surface expression of CTR
in the AMY3R for the R281A, N286A, D287A, C289A,
W290A, T295A, L297A, L298A, Y299A, and I300A mutants
within ECL2, with decreased expression to a lesser extent also
seen with Y284A, F285A, L291A, and S292A mutants within
this loop (Figure 1B,C). In general, the pattern of effect was
similar to that seen with the CTR expressed alone17 (Figure
1E,F) although greater loss of expression was seen for the
L291A and S292A mutants when the receptor was coexpressed
with RAMP3. Alanine mutation within ECL3 had less overall
impact relative to ECL2, with moderate, significant, decreases
in expression for F356A, V357A, P363A, N365A, L286A,
D373A, and Y374A, and increases for F359A and P360A
(Figure 1B,C). The lack of effect of K370A and I371A
mutation of the AMY3R was in marked contrast to the effect of
these mutants in the absence of RAMP3, where there was
almost undetectable levels of CTR expression, and very high
levels of expression observed for the P360A mutation (Figure
1E,F), although overall there was only limited impact of
mutation in ECL3. Although RAMP3 is overexpressed relative
to CTR in the bicistronic vector, it is likely that both AMY3R
and CTR alone forms of the receptor are formed. Nonetheless,
the marked difference in surface expression of the K370A and
I371A mutants (100% versus <5% for AMY3R and CTR,
respectively) supports that the cocomplex with RAMP3
accounts for the majority of receptors in the CV-1 cells.
Peptide Affinity (Competition Binding). To specifically
examine the impact of mutation on the affinity of peptide
ligands for the AMY3R, radioligand competition binding
studies were performed with 125I-rAmylin. We have previously
demonstrated that there is no measurable specific binding to
CTR alone at the concentrations of radioligand used.18 No
specific binding was detected for the R281A, Y284A, N286A,
D287A, C289A, W290A, L291A, T295A and I300A mutants in
ECL2, or for the V357A, P360A, W361A R362A, P363A,
L368A, D373A, and M376A mutants in ECL3 (Table 1, Figure
2). Many of these within ECL2 also had low cell surface
expression (Figure 1C). In contrast, there was moderate to
strong cell surface expression of most ECL3 mutants indicating
that the loss of binding was likely due to alterations to binding
affinity of the radioligand. Of those mutants with a robust
specific binding window, there was a subset that exhibited loss
of affinity, in a peptide specific manner (Table 1, Figure 2,
Figures S1−S6). hCGRP was least impacted, with no
significant change in observed affinity (Figure S1E). There
was a selective loss of rAmy affinity for the E294A and G369A
mutants (Figure S1D), of hCT for the T280A, L298A, and
S364A mutants (Figure S1B), of sCT for the K366A mutant,
and pCT for the N288A mutant (Figures S1A and S1C,
respectively). F285A and Y299A displayed a selective loss of
affinity for CT peptides with no significant effect on rAmy or
hCGRP. Similarly, there was loss of affinity for all CT peptides
for the V358A and F359A mutants; rAmy affinity was also
decreased at V358A (Table 1, Figures S1A−D). There was
selective loss of affinity for sCT and pCT at the V283A mutant,
hCT, pCT, and rAmy at the L297A and Y372A mutants, and
Figure 2. Identification of key amino acids of AMY3R ECL2 and
ECL3 for peptide binding affinity (log Ki). (A) sCT; (B) hCT; (C)
pCT; (D) rAmy; (E) hCGRP. Mutations that significantly decreased
peptide affinity in radioligand competition assay are colored dark
orange (≤10-fold effect) or red (>10-fold effect), with mutated amino
acids without significant alteration to log Ki colored gray. Amino acid
mutations where there was an insufficiently robust functional effect to
quantify by radioligand competition binding are depicted in black.
The receptor ECD is not shown for clarity, with the CTR TM bundle
in blue ribbon and RAMP3 in green ribbon. Quantitative data are
reported in Table 1.
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of hCT and pCT at the F356A and M367A mutants (Table 1,
Figures S1A−D). The effect of mutations within ECL2
appeared to coincide with residues known to contribute to
packing of ECL2 in CTR16 or were in close proximity to the
predicted RAMP3 interface (Figure 2). In contrast, the effect
of most mutations within ECL3 were consistent with potential
peptide binding interfaces and differential strength of
interaction for individual peptides (Figure 2).
Peptide Functional Affinity. For each peptide, concen-
tration−response isotherms were established in assays of
cAMP accumulation and pERK1/2 (Figures S7−S16), and
data were analyzed by operational modeling to derive estimates
of functional affinity (log KA) (Figures 3 and 4, Tables 2 and
3) and efficacy (log τ) for each pathway; the latter were
corrected for differences in cell surface expression (Figures 6
and 7, Tables 4 and 5).
There was a marked peptide dependence in the effect of
mutation on cAMP functional affinity, with the greatest impact
on hCT and pCT across both ECL2 and ECL3 (Figure 3,
Table 2). hCGRP functional affinity was minimally affected by
mutation with significant loss of affinity for L368A, but no
detectable response (ND) for C289A, P363A, and D373A
(Figures 3A,B; and 5E). Similarly, there was only limited effect
on rAmy functional affinity, with loss of affinity for W290A and
L291A in ECL2 and F359A, P363A, L368A, and D373A in
ECL3 (Figures 3D,I; 5D). For sCT, only V357A in ECL3
altered affinity, with greater impact in ECL2 with decreased
functional affinity for D287A, W290A, S292A and I300A
(Figures 3A,B; 5A). In distinction to the limited effects of
mutations on responses to these peptides, there was very
marked, extended impact on hCT and pCT (Figures
3B,C,G,H; 5B,C). Within ECL2 and the TM5 proximal
segment of ECL3, there was very similar impact on cAMP
functional affinity for both peptides with attenuated affinity for
R281A (ND for hCT), N286A, D297A, C289A, W290A (ND
for hCT), L291A, S292A, T295A, and L297A-I300A within
ECL2, and F359A-P363A in ECL3, with the exception of
L297A, L298A, and V358A that had no significant effect on
pCT affinity. Similarly, there was parallel loss of affinity for
Y372A, D373A, and M376A for both peptides. Nonetheless,
divergent effects were seen for K366A, M367A, and V375A
(selective increased affinity for pCT), and L368A (selective
Table 1. Effect of Single Alanine Mutation in AMY3R ECL2 or ECL3 on Binding Affinity (log Ki) of Peptides Derived from
Competition Binding Isothermsa
aLog Ki values were derived for each ligand and mutant receptor from analysis of either homologous (rAmy) or heterologous (sCT, hCT, pCT,
hαCGRP) competition of 125I-rAmy binding. Mean, S.E.M. and the individual experimental “n” values are reported. Significance of changes in log
Ki of each ligand was determined by comparison of mutant receptors to WT values by a one-way ANOVA and Dunnett’s post-test (p < 0.05
denoted by bold coloured entries. Orange, significant decrease ≤10-fold; red, significant decrease >10-fold). Gray shading indicates mutants where
robust radioligand binding was not detected. N.D. indicates that no value could be derived due to lack of robust competition and high data
variance.
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decreased affinity for hCT) (Figures 3B,C,G,H; 5B,C; Table
2).
In contrast to the dramatic effect on cAMP functional
affinity, there was no significant effect on measured pERK
functional affinity for any of the peptides (Figures 4 and 5,
Table 3). However, robust responses were not seen for the
following mutants and peptides; R281A (hCT), D287A (hCT,
pCT, hCGRP), C289A (hCT, rAmy), W290A (hCGRP),
L291A (hCT, hCGRP), L298A, I300A, P360A (hCGRP),
R362A, P363A (rAmy, hCGRP), K370A (rAmy), I371A
(hCT, rAmy, hCGRP), D373A, V375A, and M376A
(hCGRP) and thus the nature of the loss of response could
not be determined.
These data revealed marked differences in how ECL2 and
ECL3 contribute to functional affinity across the two pathways
at the AMY3R (Figure 5). The most notable differences were
seen for hCT and pCT for which there was broad importance
of the amino acids in the core of ECL2, and peptide proximal
residues of ECL3, in cAMP but not pERK functional affinity
(Figure 5B,C versus Figure 5G,H). Alanine mutants that
selectively increased cAMP functional affinity for pCT
clustered away from the peptide binding site and were located
on the periphery of the receptor transmembrane domain. This
region would be predicted to interact with the membrane
bilayer, suggesting that these candidate receptor-membrane
interactions constrain the receptor in a way that limits pCT
functional affinity when RAMP3 is present, as the effect of
mutation was not seen with mutants of CTR alone17 (Figure
6C versus Figure 6H). For the other peptides, there was
limited effect of loop mutation on functional affinity for either
pathway, with the quantifiable effects primarily occurring
within residues involved in packing of the ECL2 in the active
structures (Figure 5). While no quantifiable effect was seen on
pERK functional affinity, there was a cluster of residues at the
apex of ECL3 that adversely affected rAmy and hCGRP
Figure 3. Alanine mutation of ECL2 and ECL3 of AMY3R alters
cAMP functional affinity (log KA) in a peptide-specific manner.
Functional affinities derived from operational fitting of concen-
tration−response curves in cAMP accumulation for alanine mutation
of ECL2 (A-E) and ECL3 (F-J) are displayed as log KA. Significance
of changes was established by comparison of the WT to the other
receptor mutants following one-way ANOVA and Dunnett’s post-test
with P < 0.05 accepted as significant. Mutants that gave significant
reductions between 3- and 10-fold are colored orange, and those with
reductions greater than 10-fold are colored red. Mutants giving
significant increases in log KA are colored green. Where data were
insufficiently robust to derive a reliable value for log KA no symbol is
shown (ND). Quantitative data are reported in Table 2.
Figure 4. Alanine mutation of ECL2 and ECL3 of AMY3R has limited
effect on pERK functional affinity (log KA). Functional affinities
derived from operational fitting of concentration−response curves in
ERK phosphorylation for alanine mutation of ECL2 (A−E) and
ECL3 (F−J) are displayed as log KA. No significant changes in log KA
from WT were seen for receptor mutants following one-way ANOVA
and Dunnett’s post-test with P < 0.05 accepted as significant. Where
data were insufficiently robust to derive a reliable value for log KA no
symbol is shown (ND). Quantitative data are reported in Table 3.
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responses, but not those of CT peptides, suggesting that they
are important for initiation or propagation of pERK signaling
(Figure 5I,J, see red arrows).
The equivalent amino acids in CTR did not impact on
pERK functional affinity of these peptides (Figure 7D,E versus
Figure 7I,J), consistent with RAMP3 allosterically altering
interaction of rAmy and hCGRP with this segment of the
receptor, potentially through effects on engagement of the
receptor with the midregion of the agonist peptide α-helix.
In general, the effect of ECL2 and ECL3 mutation was
similar for AMY3R and CTR for cAMP functional affinity
(Figure 6), for most peptides, although RAMP3 appeared to
impart increased sensitivity to mutation for hCT and pCT.
The exception to this was hCGRP in which a greater effect of
mutation was seen for CTR relative to AMY3R (Figure 6E
versus Figure 6J), and this might reflect increased strength of
interaction of this peptide at the AMY3R such that individual
mutation of amino acids had lesser effect.
Intriguingly, while overall there was relatively limited impact
of ECL2 or ECL3 mutation on pERK functional affinity for
either AMY3R or CTR, there was a greater effect of mutation
on CTR, particularly for CT peptides and within ECL3 (Figure
7A-C versus 7F−H). This greater effect on CTR mutation
occurred for select amino acids deep in the peptide binding
pocket, with additional effects on pCT for residues that
extended, in 3D space, from the peptide proximal residues.
Peptide Efficacy. The operationally derived efficacy
parameter, τ, is a measure of pathway-specific coupling
efficiency that relates the number of receptors occupied to
response.19 Peptide efficacy for cAMP accumulation was
largely unaffected by mutation to ECL2 residues (Figure
8A−E, Table 4), albeit that the relatively high variance may
have limited those effects that achieved statistical significance.
Overall, ECL2 mutation tended to lead to increased
measures of peptide efficacy for CT peptides (Figure 8A−
C), with effects achieving significance for S292A mutation
(sCT, pCT), L298A (sCT) and I300A (hCT). Increased
efficacy of rAmy was also observed with the S292A mutant
(Figure 8D). In contrast, both increased and decreased efficacy
was observed following mutation of amino acids in ECL3, in a
peptide-dependent manner (Figure 8F−J). Greater numbers of
mutations had significant effects within ECL3; however, this
was partially attributable to more robust expression of ECL3
Table 2. Effect of Single Alanine Mutation in AMY3R ECL2 or ECL3 on cAMP Functional Affinity (log KA) of Peptides
a
aFor each receptor mutant and ligand, concentration−response data for each pathway were fit with the Black and Leff operational model to derive
an affinity-independent measure of efficacy and functional affinity (log KA). Mean, S.E.M., and the individual experimental “n” values are reported.
Significance of changes in log KA of each ligand was determined by comparison of mutant receptors to WT values by a one-way ANOVA and
Dunnett’s post-test (p < 0.05 denoted by bold coloured entries. Orange, significant decrease ≤ 10-fold; red, significant decrease > 10-fold; Light
green, significant increase ≤ 10-fold; Dark green, significant increase > 10-fold). ND, data were not able to be reliably determined.
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mutants (Figure 1, Table 1) and greater precision in the
calculation of log τ (Table 4).
The pattern of effect was similar for CT peptides, with
increased efficacy for each peptide observed with the F356A,
V358A, N365A, and D373A mutants and loss of efficacy for
the V375A mutant (Figure 8F−H). Nonetheless, peptide
specific effects were also observed with increased efficacy at the
V358A (sCT), F359A (sCT, pCT), W361A (sCT), and
M376A (sCT) mutants. Selective attenuation of efficacy was
seen at the G369A and K370A (hCT) and Y372A (pCT)
mutants (Figure 8F−H). While there were parallels in the
effect of the F356A and N365A mutation for rAmy and
hCGRP, the pattern of effect was generally distinct (Figure
8I,J), and more similar for these two peptides than between
them and the CT peptides (Figure 8F−J). Of all the ECL3
mutants, only the F356A and N365A mutants had equivalent
effect (increased efficacy) on rAmy, hCGRP, and CT peptides,
while the effects of increased efficacy (V357A) and decreased
efficacy (V375A) were also observed for rAmy but not
hCGRP. Similar effects, distinct from those for CT peptides,
were observed for both rAmy and hCGRP for P360A, W361A,
P363A, and D373A (decreased efficacy or ND), with the
nature of effect of the D373A mutant opposite to that seen for
all CT peptides (Figure 8F−J). Peptide-specific loss of efficacy
was seen for V358A, F359A, R362A, Y372A (hCGRP),
M367A, and G369A (rAmy) (Figure 8I,J).
Remarkably, there was a dramatic loss of peptide efficacy for
pERK for most individual mutants within both ECL2 and
ECL3 (Figure 9, Table 5), although there was a lesser effect of
ECL2 mutation on hCGRP efficacy (Figure 9E). Within
ECL2, only I279A did not have any negative effect on CT or
Amy peptide efficacy, albeit that the loss of efficacy did not
achieve significance for V283A (hCT, pCT, rAmy), Y284A
(rAmy), N288A (hCT), V293A (pCT), E294A, H296A (sCT,
hCT, pCT, rAmy), L297A (hCT, pCT, rAmy), and L298A
(hCT) (Figure 9A−D, Table 5). As noted above, for hCGRP,
no robust response was observed for D287A, L291A, L298A,
and Y299A (Tables 3, 5). Of the other ECL2 mutants, only the
S292A mutant produced a significant loss of hCGRP efficacy
(Figure 9E). Like ECL2, alanine mutation of ECL3 broadly led
to loss of peptide efficacy (Figure 9F−J). For this loop, the
pattern of effect was also mirrored for hCGRP (Figure 9J). Of
the ECL3 residues, only S364A, N365A, and Y284A did not
significantly reduce efficacy of any of the peptides (Table 5).
For W361A and L368A, while loss of efficacy occurred for all
peptides, this was not statistically significant for some of the
Table 3. Effect of Single Alanine Mutation in AMY3R ECL2 or ECL3 on pERK Functional Affinity (log KA) of Peptides
a
aFor each receptor mutant and ligand, concentration−response data for each pathway were fit with the Black and Leff operational model to derive
an affinity-independent measure of efficacy and functional affinity (log KA). Mean, S.E.M. and the individual experimental “n” values are reported.
ND, data were not able to be reliably determined. Where quantitative data could be derived, no significant differences from WT values were
observed, as assessed by a one-way ANOVA and Dunnett’s post-test (significance set at p < 0.05).
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peptides. Of the other mutants only K370A (hCT), F357A,
and D373A (hCGRP) did not have significant effects on pERK
peptide efficacy (Figure 9F−J).
Mapping the effects of ECL2 and ECL3 mutation onto the
3D AMY3R model revealed major differences in the effect of
alanine mutation on the two signaling pathways (Figure 10).
Mutations through the core of ECL2 dramatically reduced CT
peptide and rAmy efficacy for pERK but had very limited
impact on the efficacy in cAMP assays (Figure 10).
Within ECL2, the most notable effect on cAMP efficacy was
increased efficacy with the S292A mutation. This contrasts to
the decreased functional affinity of the CT peptides for this
pathway. S292 is capable of forming polar interactions and, in
the CTR, contributes to packing of ECL2 in the active state.16
Nonetheless, in CTR the S292A mutation does not alter either
affinity or efficacy of peptides for this pathway.17 This suggests
that RAMP3 allosterically alters CTR ECL2 conformation,
potentially allowing this residue to interact with rAmy and CT
peptides when coupled to Gs.
Within ECL3, the mutation of residues at the proximal end
of TM6 that are located deep in the peptide binding pocket led
to enhanced cAMP efficacy for all peptides (Figure 10A−E).
Interestingly, N365, whose alanine mutation also enhanced
cAMP efficacy for all peptides, is located at the external face of
the receptor (Figure 10A−E), and thus may make polar
interactions with lipid head groups that constrain conforma-
tional propagation for Gs engagement in the context of the
AMY3R. This amino acid was one of very few that did not
adversely affect pERK efficacy (Figure 10A−E versus Figure
10F−J), suggesting that such a constraint does not affect non-
Gs pathways. We have previously shown that pERK is
independent of cAMP-dependent PKA activity, and PTX-
sensitive Gi/o proteins for the AMY3R
7 indicating that, like
CTR, the effect of mutations on the two measured pathways
reveal distinct conformational propagation pathways. Compar-
ison of the effect of mutation on AMY3R and CTR pointed to
peptide-specific influence on cAMP efficacy (Figure 11).
Intriguingly, while the pattern of effect was similar, alanine
mutation in ECL3 had greater impact on sCT efficacy at
AMY3R compared to CTR, with mutation of the deeper,
peptide-proximal residues within ECL3 enhancing cAMP
efficacy (Figure 11A versus Figure 11F), implying a role for
Table 4. Effect of Single Alanine Mutation in AMY3R ECL2 or ECL3 on cAMP Signaling Efficacy (log τc) of Peptides
a
aFor each receptor mutant and ligand, concentration−response data for each pathway were fit with the Black and Leff operational model to derive
an affinity-independent measure of efficacy (log τ) and functional affinity. These data were corrected for changes in cell surface expression from
FACS to yield Log τc. Mean, S.E.M., and the individual experimental “n” values are reported. Significance of changes in log τc of each ligand was
determined by comparison of mutant receptors to WT values by a one-way ANOVA and Dunnett’s post-test (p < 0.05 denoted by bold coloured
entries. Orange, significant decrease ≤ 10-fold; red, significant decrease > 10-fold; light green, significant increase ≤ 10-fold; dark green, significant
increase > 10-fold). ND, data were not able to be reliably determined.
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RAMP3 in directing the conformation change required for
activation of the Gs pathway for this peptide. For hCT,
RAMP3 in AMY3R appeared to shift the path of change from
ECL2 to ECL3, based on the shift in mutational sensitivity
between the two receptors (Figure 11B,G), while, in 3D
representation, the effect of mutation of pCT cAMP response
was similar across AMY3R and CTR (Figure 11C,H).
The largest divergence between the effect of mutation for
AMY3R and CTR, on peptide-mediated cAMP efficacy,
occurred for rAmy, in which, outside of deep pocket residues
described above, mutation in ECL3 was generically associated
with loss of efficacy for AMY3R but had limited effect on CTR
(Figure 11D,I). This is consistent with the selective enhance-
ment of rAmy affinity and potency seen at the AMY3R. While
hCGRP potency is also enhanced at the AMY3R, this effect is
less prominent than that induced by RAMP1.20 As such, it is
perhaps unsurprising that the effect of mutation on hCGRP
cAMP efficacy at the AMY3R was generally similar to that
observed for CTR (Figure 11E,J).
Among the most profound differences in the effect of
mutation on AMY3R versus CTR was the effect on pERK
efficacy (Figure 12). For the CTR, there was minimal observed
effect of ECL2 and ECL3 mutation on CTR-mediated pERK
(Figure 12F−J). In contrast, there was broad loss of pERK
efficacy for mutation of AMY3R across both ECL2 and ECL3
(Figure 12A−E), supporting a model in which RAMP3 causes
a switch in the intracellular transducers engaged by CTR that
are linked to the pERK pathway. While there has not been
much investigation into the pathways linked to pERK
downstream of AMY3R and CTR, the use of pathway
inhibitors has implicated PKC, PI3K, and PLC in the
phosphorylation of ERK.7 While those studies suggested
subtle differences in the effect of inhibitors between AMY3R
and CTR,7 the mechanistic basis for the major changes to
sensitivity of mutants for AMY3R versus CTR remains to be
elucidated. Nonetheless, they suggest that RAMP3 alters
conformational propagation at least through ECL2 and ECL3.
The exception to this was hCGRP that exhibited a similar
pattern of mutational effect for both receptor phenotypes
(Figure 12E,J). This lack of effect may reflect the limited
induction of hCGRP binding and signaling that occurs with
RAMP3, relative to CTR alone, when compared to the
phenotypic induction by RAMP1.20
Table 5. Effect of Single Alanine Mutation in AMY3R ECL2 or ECL3 on pERK Signaling Efficacy (log τc) of Peptides
a
aFor each receptor mutant and ligand, concentration−response data for each pathway were fit with the Black and Leff operational model to derive
an affinity-independent measure of efficacy (log τ) and functional affinity. These data were corrected for changes in cell surface expression from
FACS to yield log τc. Mean, S.E.M., and the individual experimental “n” values are reported. Significance of changes in log τc of each ligand was
determined by comparison of mutant receptors to WT values by a one-way ANOVA and Dunnett’s post-test (p < 0.05 denoted by bold coloured
entries. Red, significant decrease > 10-fold). ND, data were not able to be reliably determined.
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■ CONCLUSION
Biased agonism is a key pharmacological behavior of both
endogenous GPCR ligands and drugs that target these
receptors. Class B GPCRs are important physiological targets
that display biased signaling in response to both endogenous
and exogenous agonists, although the mechanistic basis for
these differential effects is unclear. In this study, we
demonstrate that the dynamic nature of CTR ECL2 and
ECL3 in propagation of signaling is fundamentally altered
when complexed with RAMP3 to form the AMY3R, despite
only having predicted direct interactions with ECL2. More-
over, the work shows that the role of these loops in receptor
signaling is highly peptide dependent, illustrating that even
subtle changes to peptide sequence may change signaling
output downstream of the receptor. The work further supports
the allosteric role proposed for RAMPs in altering GPCR
function21−25 with these changes, as assessed in the current
study, extending well beyond the RAMP-CTR interface. While
full understanding of these findings will likely require solution
of structures of CTR:RAMP3 along with individual agonist
peptides and transducer proteins, the current work advances
our understanding of peptide control of class B GPCR
signaling and the molecular basis for RAMP modulation of
receptor function.
■ METHODS
Reagents. All peptides were purchased from Mimotopes.
Dulbecco’s Modified Eagle’s Medium (DMEM) was purchased
from Invitrogen. Fetal bovine serum (FBS) was purchased
from ThermoFisher Scientific. AlphaScreen reagents, Lance
cAMP kit, and 384-well Optiplates were purchased from
PerkinElmer. SureFire ERK1/2 reagents were obtained from
TGR Biosciences and PerkinElmer. Antibodies were purchased
from R&D Systems and ThermoFisher. All other reagents were
purchased from Sigma-Aldrich or BDH Merck and were of an
analytical grade.
Mutagenesis. Desired mutations were introduced to N-
terminally c-Myc tagged human CTR in pENTER11
(Invitrogen) as previously described,17 then LR recombination
reactions were conducted to transfer mutated and wild-type
(WT) receptor into the pEF5/FRT/Rluc-8/IRES/RAMP3/
Venus destination vector using Gateway Technology (In-
vitrogen), similar to our previously reported design of
Figure 5. Alanine mutation of ECL2 and ECL3 of AMY3R alters
functional affinity (log KA) in a peptide- and pathway-specific manner.
Functional affinities derived from operational fitting of concen-
tration−response curves in cAMP accumulation (A−E) and pERK
(F−J) are displayed as Δlog KA from wild-type. Illustrated is a top
view of the AMY3R model with the extracellular surface subject to
alanine scanning depicted (combined surface/cpk representation).
Mutations that significantly alter peptide functional log KA are colored
according to the magnitude of effect, with mutated amino acids
without significant alteration to log KA colored gray. Amino acid
mutations for which there was an insufficiently robust functional effect
to quantify by operational modeling are depicted in black. The
receptor ECD and peptide are not shown for clarity, with the CTR
TM bundle in blue ribbon and RAMP3 in green ribbon. Red arrows
in panels I and J indicate residues at the apex of ECL3 that are
affected for Amy and CGRP but not CT peptides.
Figure 6. Alanine mutation of ECL2 and ECL3 has distinct effects on
AMY3R and CTR cAMP functional affinity (log KA). Functional
affinities derived from operational fitting of concentration−response
curves in cAMP accumulation are displayed as Δlog KA from wild-
type for AMY3R (A−E) and CTR (F−J). Illustrated are top views of
the receptors with the extracellular surface subject to alanine scanning
depicted (combined surface/cpk representation). Mutations that
significantly alter peptide functional log KA are colored according to
the magnitude of effect, with mutated amino acids without significant
alteration to log KA colored gray. Amino acid mutations where there
was an insufficiently robust functional effect to quantify by operational
modeling are depicted in black. The receptor ECD and peptide are
not shown for clarity, with the CTR TM bundle in blue ribbon and
RAMP3 in green ribbon in panels A−E, and CTR TM bunding in red
ribbon in panels F−J. Data for CTR functional affinity are from Dal
Maso et al., 2018.17
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bicistronic constructs.26 Mutants were confirmed by auto-
mated-sequencing.
Stable Cell Line Generation and Cell Culture. The
mutant or WT receptor genes were integrated into FlpIn-CV1
cells using Flp-In system (Invitrogen). Stable Flp-In expression
cell lines were generated through polyclonal selection and
screening and maintained in DMEM supplemented with 5%
(v/v) FBS, 300 μg/mL hygromycin B (Invitrogen) at 37 °C in
5% CO2. Independent WT controls were established for each
of the ECL2 and ECL3 mutants, as these were created at
different times.
Whole Cell Competition Binding Assay. Radioligand
competition binding was performed as previously described17
on whole cells seeded into 96-well plates and cultured
overnight, except that 125I-rAmy was used as the radioligand.
For homologous competition binding experiments, cells were
incubated overnight at 4 °C with ∼100 pM 125I-rAmy (specific
activity, 2000 Ci/mmol) and serial dilutions of non-iodinated
rAmy, while heterologous competition was in the presence of
increasing concentrations of unlabeled peptide. Non-bound
ligand was removed and bound ligand activity was measured
using a γ counter (Wallac Wizard 1470 Gamma Counter,
PerkinElmer, 78% counter efficiency). Values were normalized
against nonspecific binding, defined by the presence of 1 μM of
unlabeled rAmy, and total ligand bound radioligand.
Cell Surface Expression Assessment by FACS. Surface
expression of AMY3R mutants stably expressed in CV-1 cells
was quantified by flow cytometry of antibody binding to the c-
Myc tagged CTR subunit of the receptor using standard
methods. Cells were grown in 6-well plates at ∼5 × 105 cells
per well the day before assay. Cells were harvested in the
presence of versene. All staining steps were conducted in ice
cold Hank’s Balanced Salt Solution (HBSS) with 0.1% bovine
serum albumin (BSA) and 20 mM HEPES (4-(2-hydrox-
yethyl)-1-piperazineethanesulfonic acid, pH 7.4). Blocking was
conducted in 5% BSA. Primary antibody staining was
performed with 5 μg/mL 9E10 (anti-c-Myc) antibody. The
secondary antibody was 1 μg/mL goat antimouse AF647
(ThermoFisher). Sytox blue was used for live/dead discrim-
Figure 7. Alanine mutation of ECL2 and ECL3 has distinct effects on
AMY3R and CTR pERK functional affinity (log KA). Functional
affinities derived from operational fitting of concentration−response
curves in pERK are displayed as Δlog KA from wild-type for AMY3R
(A−E) and CTR (F−J). Illustrated are top views of the receptors with
the extracellular surface subject to alanine scanning depicted
(combined surface/cpk representation). Mutations that significantly
alter peptide functional log KA are colored according to the magnitude
of effect, with mutated amino acids without significant alteration to
log KA colored gray. Amino acid mutations where there was an
insufficiently robust functional effect to quantify by operational
modeling are depicted in black. The receptor ECD and peptide are
not shown for clarity, with the CTR TM bundle in blue ribbon and
RAMP3 in green ribbon in A-E, and CTR TM bunding in red ribbon
in F-J. Data for CTR functional affinity are from Dal Maso et al.,
2018.17
Figure 8. Alanine mutation of ECL2 and ECL3 of AMY3R alters
cAMP efficacy (log τc) in a peptide-specific manner. Peptide efficacy
(log τ) was derived from operational fitting of concentration−
response curves in cAMP accumulation for alanine mutation of ECL2
(A−E) and ECL3 (F−J), and corrected for cell surface receptor
expression to yield Log tauc. Significance of mutation effect was
established by comparison of the WT to the other receptor mutants
following one-way ANOVA and Dunnett’s post-test with P < 0.05
accepted as significant. Mutants that significantly reduced log τc are
colored orange (≤10-fold change), or red (>10-fold change). Mutants
that significantly increased log τc are colored green (≤10-fold change,
light green; >10-fold, dark green). Where data were insufficiently
robust to derive a reliable value for log τc no symbol is shown (ND).
Quantitative data are reported in Table 4.
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ination. Data were collected on a FACS CantosII (BD
Biosciences) with at least 20 000 live cells collected per
sample. WT stained CTR sample and stained parental CV-1
cells were collected at the beginning and the end of each run.
Data were analyzed using FlowJo. The mean AF647
fluorescence intensity from each sample for a particular
experiment was normalized against parental (0%) and WT
CTR (100%) controls.
cAMP Accumulation Assay. Cells (2.5 × 104 cells/well)
were seeded into 96-well plates and incubated overnight.
Complete media was replaced with phenol red-free DMEM
containing 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) and
0.1% BSA and preincubated for 30 min. Cells were stimulated
with increasing concentrations of ligands for 30 min in the
presence of 0.5 mM 3-isobutyl-1-methylxanthine (IBMX). The
media was discarded, changed to absolute ethanol and
volatilized to dryness at room temperature. Samples were
then lysed and intracellular cAMP was detected using the
PerkinElmer Lance kit as previously described.14 Data were
normalized to the maximal response of each peptide.
ERK1/2 Phosphorylation. Cells (2.5 × 104 cells/well)
were seeded into 96-well culture plates and incubated
overnight. Initially, pERK1/2 time-course experiments were
performed over 30 min to identify the time point when the
pERK1/2 response is maximal (6−8 min). Subsequently, this
time point was selected to generate concentration response
curves for different agonists with ligand addition performed
after overnight serum starvation with DMEM. FBS was used as
a positive control. pERK1/2 was detected using an
AlphaScreen assay as previously described.27 Data were
normalized to the maximal response elicited by each peptide.
Pharmacological Data Analysis. IC50 and Bmax values
were estimated from competitive inhibition of 125I-rAmy
binding using a three-parameter logistic equation [Log-
(inhibitor versus response)] in Prism (v7 or v8; GraphPad).
The concentration of the radioligand was ≤ 5% of the KD
values. Under these conditions, the IC50 approximates Ki, and
such data are reported as log Ki. The Black and Leff
operational model of partial agonism19,27 was applied to
separate effects on pathway-specific efficacy (defined by the
value tau, τ) from those that modify ligand functional affinity
(log KA). Derived τ values were normalized to experimentally
Figure 9. Alanine mutation of ECL2 and ECL3 of AMY3R alters
pERK efficacy (log τc) in a peptide-specific manner. Peptide efficacy
(log τ) was derived from operational fitting of concentration−
response curves in pERK for alanine mutation of ECL2 (A−E) and
ECL3 (F−J), and corrected for cell surface receptor expression to
yield log τc. Significance of mutation effect was established by
comparison of the wild-type to the other receptor mutants following
one-way ANOVA and Dunnett’s post-test with P < 0.05 accepted as
significant. Mutants that significantly reduced log τc are colored
orange (≤10-fold change), or red (>10-fold change). Where data
were insufficiently robust to derive a reliable value for log τc no
symbol is shown (ND). Quantitative data are reported in Table 5.
Figure 10. Alanine mutation of ECL2 and ECL3 of AMY3R alters
peptide efficacy (log τc) in a pathway-specific manner. Efficacy values
derived from operational fitting of concentration−response curves in
cAMP accumulation (A−E) and pERK (F−J) are displayed as Δlog τc
from wild-type. Illustrated is a top view of the AMY3R model with the
extracellular surface subject to alanine scanning depicted (combined
surface/cpk representation). Mutations that significantly alter peptide
log τc are colored according to the magnitude of effect, with mutated
amino acids without significant alteration to log τc colored gray.
Amino acid mutations for which there was an insufficiently robust
functional effect to quantify by operational modeling are depicted in
black. The receptor ECD and peptide are not shown for clarity, with
the CTR TM bundle in blue ribbon and RAMP3 in green ribbon.
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determined levels of cell surface expression to provide a
measure of efficacy (τc) that is independent of affinity and
altered cell surface receptor expression.28 pKi, pKA, and log τc
values for mutant receptors were statistically compared to
those of the respective WT receptor using a one-way analysis
of variance (ANOVA) and Dunnett’s post-test. Significance
was accepted at P < 0.05.
Computational Methods. System Preparation. The
CTR:RAMP3 complex was built using the Modeler com-
parative modeling program from the full CGRPR15 and CTR16
3.3 Å cryo-EM receptor structures, which included the missing
loops, and the 1.76 Å CLR:RAMP2 X-ray crystal structure of
the extracellular domain of the adrenomedullin receptor29
(PDB codes 6E3Y, 6NIY, and 4RWF, respectively). The
disulfide bond between RAMP3 residues Cys 28 and Cys 72
was included. The structure with the best discrete optimized
protein energy (DOPE) score30 out of 1000 generated models
was prepared for molecular dynamics simulation using a
combination of python htmd31 and tcl (Tool Command
Language) scripts. Hydrogen atoms were added using pdb
2pqr;32 the protonation state of titratable side chains was
determined using propka33 (run at pH 7) coupled with visual
inspection. The systems were embedded in a pre-existing 1-
palmitoyl-2-oleyl-sn-glycerol-3-phospho-choline (POPC) bi-
layer using an insertion method,34 with overlapping lipids
removed. The receptor orientation was determined from the
Calcitonin receptor-Gs complex (PDB ID: 5UZ7) entry in the
OPM database.35 TIP3P water molecules36 were added to the
106 Å × 106 Å × 141 Å simulation box using the VMD Solvate
plugin version 1.5 (http://www.ks.uiuc.edu/Research/vmd/
plugins/solvate/). Sodium and chloride ions were added to
mimic an ionic strength of 0.150 M and to obtain overall
charge neutrality, using the VMD Autoionize plugin 1.3
(Autoionize Plugin, Version 1.3. at < http://www.ks.uiuc.edu/
Research/vmd/plugins/autoionize/).
Systems Equilibration and MD Settings. The MD engine
ACEMD37 was employed for both the equilibration and
productive simulations, which employed the CHARMM36
force field.38 Equilibration was achieved in isothermal−isobaric
conditions (NPT) using the Langevin thermostat39 (target:
300 K) with a low damping of 1 ps−1 and the Berendsen
barostat40 (target: 1 atm) over a three-stage procedure using
an integration time step of 2 fs. First, clashes between protein
and lipid atoms were reduced through 2500 conjugate-gradient
Figure 11. Alanine mutation of ECL2 and ECL3 has distinct effects
on cAMP peptide efficacy for AMY3R and CTR. Peptide efficacy,
derived from operational fitting of concentration−response curves in
cAMP accumulation, are displayed as Δlog τc from wild-type for
AMY3R (A−E) and CTR (F−J). Illustrated are top views of the
receptors with the extracellular surface subject to alanine scanning
depicted (combined surface/cpk representation). Mutations that
significantly alter peptide functional log τc are colored according to
the magnitude of effect, with mutated amino acids without significant
alteration to log τc colored gray. Amino acid mutations for which
there was an insufficiently robust functional effect to quantify by
operational modeling are depicted in black. The receptor ECD and
peptide are not shown for clarity, with the CTR TM bundle in blue
ribbon and RAMP3 in green ribbon in A−E, and CTR TM bunding
in red ribbon in F−J. Data for CTR peptide efficacy are from Dal
Maso et al., 2018.17
Figure 12. Alanine mutation of ECL2 and ECL3 has distinct effects
on pERK peptide efficacy for AMY3R and CTR. Peptide efficacy,
derived from operational fitting of concentration−response curves in
pERK, are displayed as Δlog τc from wild-type for AMY3R (A−E) and
CTR (F−J). Illustrated are top views of the receptors with the
extracellular surface subject to alanine scanning depicted (combined
surface/cpk representation). Mutations that significantly alter peptide
functional log τc are colored according to the magnitude of effect, with
mutated amino acids without significant alteration to log τc colored
gray. Amino acid mutations for which there was an insufficiently
robust functional effect to quantify by operational modeling are
depicted in black. The receptor ECD and peptide are not shown for
clarity, with the CTR TM bundle in blue ribbon and RAMP3 in green
ribbon in A−E, and CTR TM bundling in red ribbon in F−J. Data for
CTR peptide efficacy are from Dal Maso et al., 2018.17
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minimization steps followed by a 2 ns long MD simulation
with a positional constraint of 1 kcal mol−1 Å−2 on protein and
lipid phosphorus atoms. Second, 33 ns of MD simulation was
performed with only the protein atoms constrained. Third,
positional constraints were applied only to the protein
backbone alpha carbons for a further 35 ns.
A 1 μs simulation was run in the canonical ensemble (NVT)
at 300 K, using a thermostat damping of 0.1 ps−1. The M-
SHAKE algorithm41 was used to constrain the covalent bonds
involving hydrogen atoms, enabling a time step of 4 fs. A 9 Å
cutoff distance was used for the electrostatic interactions, with
a switching function applied beyond 7.5 Å; long-range
Coulomb interactions were handled using the particle mesh
Ewald summation method (PME)42 with a mesh spacing to 1.0
Å. The mutagenesis results were plotted on the 200 ns
structure, since this was deemed sufficient to remove any strain
within the initial structure.
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